Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2022 08:00 ET | Source: Triphase Accelerator

Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma

High response rates: ORR of 54% and a CR rate of 38%Durable responses: ~25 months median duration of response Favourable safety profile: AEs predominantly low grade, tolerable, easily managed, and...
December 07, 2020 16:30 ET | Source: Triphase Accelerator

Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today...
January 29, 2019 07:00 ET | Source: Triphase Accelerator

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy

TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class...